Are Longeveron's Mesenchymal Stem Cells effective against frailty in ageing?
CISION PR Newswire - 01-Jun-2020Japan's Pharmaceutical and Medical Devices Agency gives the green light for human trials
Join the club for FREE to access the whole archive and other member benefits.
President of Longeveron LLC
Geoff Green has been with Longeveron since 2016, previously as SVP of Clinical Operations. Mr. Green is a versatile executive with over 20 years of experience in leadership roles in the life sciences industry. His background spans clinical drug development, clinical operations, and business and corporate development. He has held the positions of VP of Operations at Partikula, VP of Business Development & Clinical Affairs at Accu-Break Pharmaceuticals, Acting President and CEO of DOR BioPharma, VP of Business Development & Operations at Heart Genomics, and Director of Clinical Affairs at IDDS. Mr. Green earned a BA in biology from Kenyon College, and an MBA from Barry University’s Andreas School of Business.
See also: Longeveron - Leading regenerative medicine company located in the Life Science & Technology Park (LSTP) in Miami, Florida
Details last updated 20-Jun-2020
Japan's Pharmaceutical and Medical Devices Agency gives the green light for human trials